Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication
Open accessThe DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
The transcription factor Yin Yang 1 (YY1) is frequently overexpressed in cancerous tissues compared to normal tissues and has regulatory roles in cell proliferation, cell viability, epithelial-mesenchymal transition, metastasis and drug/immune resistance. YY1 shares many properties with cancer stem cells (CSCs) that drive tumorigenesis, metastasis and drug resistance and are regulated by overexpression of certain transcription factors, including SOX2, OCT4 (POU5F1), BMI1 and NANOG. Based on these similarities, it was expected that YY1 expression would be associated with SOX2, OCT4, BMI1, and NANOG's expressions and activities. Data mining from the proteomic tissue-based datasets from the Human Protein Atlas were used for protein expression patterns of YY1 and the four CSC markers in 17 types of cancer, including both solid and hematological malignancies. A close association was revealed between the frequency of expressions of YY1 and SOX2 as well as SOX2 and OCT4 in all cancers analyzed. Two types of dynamics were identified based on the nature of their association, namely, inverse or direct, between YY1 and SOX2. These two dynamics define distinctive patterns of BMI1 and OCT4 expressions. The relationship between YY1 and SOX2 expressions as well as the expressions of BMI1 and OCT4 resulted in the classification of four groups of cancers with distinct molecular signatures: (1) Prostate, lung, cervical, endometrial, ovarian and glioma cancers (YY1(lo)SOX2(hi)BMI1(hi)OCT4(hi)) (2) Skin, testis and breast cancers (YY1(hi)SOX2(lo)BMI1(hi)OCT4(hi)) (3) Liver, stomach, renal, pancreatic and urothelial cancers (YY1(lo)SOX2(lo)BMI1(hi)OCT4(hi)) and (4) Colorectal cancer, lymphoma and melanoma (YY1(hi)SOX2(hi)BMI1(lo)OCT4(hi)). A regulatory loop is proposed consisting of the cross-talk between the NF-kB/PI3K/AKT pathways and the downstream inter-regulation of target gene products YY1, OCT4, SOX2 and BMI1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Fasano, C. A., Dimos, J. T., Ivanova, N. B., Lowry, N., Lemischka, I. R., & Temple, S. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.04.001 · Cited by 301
RetractedTissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672 · cited 1×
“EMT has been shown to cause reversion to a CSC-like phenotype, linking CSCs, EMT and drug resistance [3, 4].”
BackgroundCore Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.020 · Cited by 4,505 · cited 1×
“SOX2, OCT4 and NANOG co-occupy the promoter regions of at least 353 genes, and NANOG has been shown to occupy >90 % of the promoter regions bound by both OCT4 and SOX2 in human embryonic stem cells [59].”
BackgroundNichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Schöler, H., & Smith, A. (1998) · Cell · doi:10.1016/s0092-8674(00)81769-9 · Cited by 3,392 · cited 1×
“OCT4, also referred to as POUF51 and OCT3/4, is another transcription factor necessary for maintaining pluripotency [57].”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 1×
“EMT has been shown to cause reversion to a CSC-like phenotype, linking CSCs, EMT and drug resistance [3, 4].”
BackgroundFunctional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., & Smith, A. (2003) · Cell · doi:10.1016/s0092-8674(03)00392-1 · Cited by 3,255 · cited 2×
“c) NANOG functions NANOG is capable of maintaining embryonic stem cell pluripotency independently of the LIF-STAT3 pathway, which OCT4 is incapable of doing [68, 73].”
BackgroundThe Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., & Yamanaka, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00393-3 · Cited by 3,191 · cited 2×
“c) NANOG functions NANOG is capable of maintaining embryonic stem cell pluripotency independently of the LIF-STAT3 pathway, which OCT4 is incapable of doing [68, 73].”
BackgroundData, information, knowledge and principle: back to metabolism in KEGG
Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1076 · Cited by 3,092 · cited 1×
“SOX2, Octamerbinding transcription factor 4 (OCT4) (the transcription factor encoded by POU5F1, also known as POU5F1) and NANOG make up the core transcriptional network responsible for the regulation of stem cell self-renewal and pluripotency [5].”
BackgroundChen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V. B., Wong, E., Orlov, Y. L., Zhang, W., Jiang, J., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.043 · Cited by 2,501 · cited 1×
“, HOXB1, PAX6, MYF5) [59, 60].”
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452 · cited 2×
“e) Clinical implications Elevated BMI1 RNA levels have been correlated with more advanced chronic myeloid leukemia status [96, 107].”
BackgroundIdentification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293 · cited 1×
“Ovarian CSCs are more resistant to cisplatin and paclitaxel when BMI1 is overexpressed [117], and targeting BMI1 sensitizes ovarian cancer cells to cisplatin [118].”
BackgroundHedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells
Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,244 · cited 1×
“Additionally, the Hedgehog pathway activates BMI1 in breast stem cells [106].”
BackgroundRudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundThe Biology of Cancer Stem Cells
Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104154 · Cited by 1,043 · cited 1×
“One subset of these cells consists of cancer stem cells (CSCs), which are largely similar to normal stem cells with respect to both their behavior and their regulation [2].”
BackgroundShi, Y., Seto, E., Chang, L.-S., & Shenk, T. (1991) · Cell · doi:10.1016/0092-8674(91)90189-6 · Cited by 1,035
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009) · Nature Genetics · doi:10.1038/ng.465 · Cited by 942 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundTumour-initiating cells: challenges and opportunities for anticancer drug discovery
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2137 · Cited by 841
Transcription factor YY1: structure, function, and therapeutic implications in cancer biology
Gordon, S., Akopyan, G., Garban, H., & Bonavida, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209080 · Cited by 756
Self-citationChew, J.-L., Loh, Y.-H., Zhang, W., Chen, X., Tam, W.-L., Yeap, L.-S., Li, P., Ang, Y.-S., Lim, B., Robson, P., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.6031-6046.2005 · Cited by 646 · cited 1×
“d) Regulation of OCT4 SOX2 and OCT4 regulate their own transcription by binding the composite sox-oct elements in the SOX2 and POU5F1 enhancers [64].”
BackgroundBmi1 is essential in Twist1-induced epithelial–mesenchymal transition
Yang, M.-H., Hsu, D. S.-S., Wang, H.-W., Wang, H.-J., Lan, H.-Y., Yang, W.-H., Huang, C.-H., Kao, S.-Y., Tzeng, C.-H., Tai, S.-K., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2099 · Cited by 631
Molofsky, A. V., He, S., Bydon, M., Morrison, S. J., & Pardal, R. (2005) · Genes & Development · doi:10.1101/gad.1299505 · Cited by 588 · cited 1×
“BMI1 promotes the proliferation of leukemic stem cells in mouse models [96], and BMI1 activates the self-renewal ability of neural stem cells [97].”
BackgroundGangemi, R. M. R., Griffero, F., Marubbi, D., Perera, M., Capra, M. C., Malatesta, P., Ravetti, G. L., Zona, G. L., Daga, A., & Corte, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-0493 · Cited by 578
Chiou, S.-H., Wang, M.-L., Chou, Y.-T., Chen, C.-J., Hong, C.-F., Hsieh, W.-J., Chang, H.-T., Chen, Y.-S., Lin, T.-W., Hsu, H.-S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2638 · Cited by 575 · cited 3×
“Both NANOG and OCT4 overexpressions are associated with both advanced cancer stage and decreased survival in oral squamous cell and lung adenocarcinomas [67].”
BackgroundInfluentialAlbertson, D. G. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.06.007 · Cited by 527 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundBmi1, stem cells, and senescence regulation
Park, I.-K., Morrison, S. J., & Clarke, M. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420800 · Cited by 495 · cited 1×
“BMI1 regulates the tumor suppressors p16INK4a and p14ARF [98, 99].”
BackgroundOctamer and Sox Elements Are Required for Transcriptional cis Regulation of Nanog Gene Expression
Kuroda, T., Tada, M., Kubota, H., Kimura, H., Hatano, S.-Y., Suemori, H., Nakatsuji, N., & Tada, T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.6.2475-2485.2005 · Cited by 486 · cited 1×
“OCT4/SOX2 heterodimers bind the NANOG proximal promoter region to induce transcription [62, 63].”
BackgroundUnlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?
Thomas, M. J., & Seto, E. (1999) · Gene · doi:10.1016/s0378-1119(99)00261-9 · Cited by 465
Everything you have ever wanted to know about Yin Yang 1......
Shi, Y., Lee, J.-S., & Galvin, K. M. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(96)00044-3 · Cited by 436 · cited 1×
“Comprised of 414 amino acids, YY1 exerts various cellular functions, including transcriptional regulation, cell proliferation, chromatin remodeling and apoptosis [124–128].”
BackgroundThe Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells.
Dimri, G. P., Martínez‐Guitarte, J., Jacobs, J. J. L., Keblusek, P., Itahana, K., van Lohuizen, M., Campisi, J., Wazer, D. E., & Band, V. (2002) · PubMed · Cited by 398
Song, L.-B., Li, J., Liao, W.-T., Feng, Y., Yu, C.-P., Hu, L.-J., Kong, Q.-L., Xu, L.-H., Zhang, X., Liu, W.-L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39374 · Cited by 398 · cited 2×
“BMI1 also directly binds the PTEN promoter, resulting in the activation of the PI3K/AKT pathway and subsequently SNAIL stabilization and EMT induction [100].”
BackgroundJeter, C. R., Liu, B., Liu, X., Chen, X., Liu, C., Calhoun-Davis, T., Repass, J., Zaehres, H., Shen, J. J., & Tang, D. G. (2011) · Oncogene · doi:10.1038/onc.2011.114 · Cited by 394 · cited 2×
“In prostate cancer cell lines, the induction of NANOG causes the upregulations of CD133 and ALDH1 [77].”
BackgroundPark, K., & Atchison, M. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9804 · Cited by 354
SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells
Herreros-Villanueva, M., Zhang, J.-S., Koenig, A., Abel, E. V., Smyrk, T. C., Bamlet, W. R., de Narvajas, A. A.-M., Gomez, T. S., Simeone, D. M., Bujanda, L., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.23 · Cited by 331 · cited 2×
“Subsequent SOX2 knockdown causes transcriptional induction of p21 and p27, resulting in cell cycle arrest and cell growth inhibition [27].”
BackgroundSong, L.-B., Zeng, M.-S., Liao, W.-T., Zhang, L., Mo, H.-Y., Liu, W.-L., Shao, J.-Y., Wu, Q.-L., Li, M.-Z., Xia, Y.-F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0094 · Cited by 329 · cited 1×
“Increased levels of BMI1 are correlated with poor prognoses in head and neck cancers [103], including in nasopharyngeal carcinoma patients [108].”
BackgroundSox2 promotes tamoxifen resistance in breast cancer cells
Piva, M., Domenici, G., Iriondo, O., Rábano, M., Simões, B. M., Comaills, V., Barredo, I., López‐Ruiz, J. A., Zabalza, I., Kypta, R., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303411 · Cited by 328 · cited 1×
“In breast cancer, SOX2 silencing restores tamoxifen sensitivity [112].”
BackgroundYang, J., Liao, D., Chen, C., Liu, Y., Chuang, T.-H., Xiang, R., Markowitz, D., Reisfeld, R. A., & Luo, Y. (2013) · Stem Cells · doi:10.1002/stem.1281 · Cited by 301 · cited 1×
“Furthermore, an EGFR/STAT3/SOX2 signaling pathway has been reported in murine breast cancer stem cells [42].”
BackgroundHariharan, N., Kelley, D. E., & Perry, R. P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9799 · Cited by 298 · cited 1×
“Yin Yang 1 (YY1) is an ubiquitously expressed zincfinger transcription factor encoded by the 23 kb YY1 gene [120–124].”
BackgroundHussenet, T., Dali, S., Exinger, J., Monga, B., Jost, B., Dembelé, D., Martinet, N., Thibault, C., Huelsken, J., Brambilla, E., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008960 · Cited by 296 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundJustilien, V., Walsh, M. P., Ali, S. A., Thompson, E. A., Murray, N. R., & Fields, A. P. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.008 · Cited by 293 · cited 1×
“Co-amplification of SOX2 and Protein Kinase CI (PRKCI) has been reported to be responsible for the CSC phenotype in lung squamous cell carcinoma [25].”
BackgroundSuzuki, A., Raya, Á., Kawakami, Y., Morita, M., Matsui, T., Nakashima, K., Gage, F. H., Rodríguez-Esteban, C., & Izpisúa Belmonte, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506945103 · Cited by 273 · cited 1×
“LIF-induced STAT3 phosphorylation also results in the upregulation of NANOG in embryonic stem cells [83].”
BackgroundSOX2 and cancer: current research and its implications in the clinic
Weina, K., & Utikal, J. (2014) · Clinical and Translational Medicine · doi:10.1186/2001-1326-3-19 · Cited by 269 · cited 1×
“Protein partners, nuclear import signals, and nuclear export signals bind the HMG domain, while the C-terminal transactivation domain is responsible for promoter binding, causing the activation or repression of target genes [10].”
BackgroundBmi-1 Is a Crucial Regulator of Prostate Stem Cell Self-Renewal and Malignant Transformation
Lukacs, R. U., Memarzadeh, S., Wu, H., & Witte, O. N. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.013 · Cited by 268 · cited 2×
“c) BMI1 functions BMI1 is involved in the maintenance and/or selfrenewal of many stem cell types, including embryonic, neural, hematopoietic and prostate [92–95].”
Backgroundvan Kemenade, F. J., Raaphorst, F. M., Blokzijl, T., Fieret, E., Hamer, K. M., Satijn, D. P. E., Otte, A. P., & Meijer, C. J. L. M. (2001) · Blood · doi:10.1182/blood.v97.12.3896 · Cited by 266
Embryonic stem cell markers expression in cancers
Schoenhals, M., Kassambara, A., Vos, J. D., Hose, D., Moreaux, J., & Klein, B. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.02.156 · Cited by 265 · cited 3×
“Bioinformatics analysis showed SOX2 overexpression in 7/36 solid tumors analyzed [16].”
BackgroundInfluentialBreastmilk Is a Novel Source of Stem Cells with Multilineage Differentiation Potential
Hassiotou, F., Beltran, A., Chetwynd, E., Stuebe, A. M., Twigger, A.-J., Metzger, P., Trengove, N., Lai, C. T., Filgueira, L., Blancafort, P., et al. (2012) · Stem Cells · doi:10.1002/stem.1188 · Cited by 263 · cited 1×
“b) SOX2 expression in various cancers SOX2 is expressed in neural stem cells [11], breast stem cells [12], and stem populations in the liver, pancreas, and stomach [13].”
BackgroundFlanagan, J. R., Becker, K. G., Ennist, D. L., Gleason, S. L., Driggers, P. H., Levi, B. Z., Appella, E., & Ozato, K. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.1.38 · Cited by 250
Bourguignon, L. Y. W., Earle, C., Wong, G., Spevak, C. C., & Krueger, K. (2012) · Oncogene · doi:10.1038/onc.2011.222 · Cited by 239
Mansukhani, A., Ambrosetti, D., Holmes, G., Cornivelli, L., & Basilico, C. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409182 · Cited by 234 · cited 1×
“Additionally, FGF induces SOX2 in osteoblasts [26].”
Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer
Meng, H.-M., Zheng, P., Wang, X.-Y., Liu, C., Sui, H.-M., Wu, S.-J., Zhou, J., Ding, Y.-Q., & Li, J. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.4.10666 · Cited by 220 · cited 1×
“Additionally, NANOG overexpression is correlated with poor prognoses for colorectal and breast cancer patients, as well as for ovarian cancer patients [85–87].”
BackgroundDong, P., Kaneuchi, M., Watari, H., Hamada, J., Sudo, S., Ju, J., & Sakuragi, N. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-99 · Cited by 220 · cited 1×
“In endometrial cancer cells, the loss of BMI1 results in the reduced expression of SOX2 and KLF4 [101].”
BackgroundAlonso, M. M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-Santiago, N., Urquiza, L., Jauregi, P., de Munain, A. L., Sampron, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026740 · Cited by 215 · cited 2×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundHedgehog controls neural stem cells through p53‐independent regulation of Nanog
Po, A., Ferretti, E., Miele, E., De Smaele, E., Paganelli, A., Canettieri, G., Coni, S., Di Marcotullio, L., Biffoni, M., Massimi, L., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.131 · Cited by 215 · cited 1×
“GLI1 and GLI2 activate NANOG transcription by directly binding cis-regulatory sequences of the NANOG gene in neural stem cells [81].”
BackgroundBourillot, P.-Y., Aksoy, I., Schreiber, V., Wianny, F., Schulz, H., Hummel, O., Hubner, N., & Savatier, P. (2009) · Stem Cells · doi:10.1002/stem.110 · Cited by 202 · cited 1×
“The two form a complex in head and neck squamous cell carcinoma cells [79], and microarray analysis showed that NANOG also regulated 14 out of the 22 STAT3 target genes involved in the maintenance of an undifferentiated state [80].”
BackgroundSOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells
Santini, R., Pietrobono, S., Pandolfi, S., Montagnani, V, D'Amico, M., Penachioni, J. Y., Vinci, M. C., Borgognoni, L., & Stecca, B. (2014) · Oncogene · doi:10.1038/onc.2014.71 · Cited by 201 · cited 1×
“In primary melanoma cells, GLI1 and GLI2 have been reported to bind the proximal SOX2 promoter, indicating that SOX2 is regulated, in part, by Hedghog-GLI signaling [43].”
BackgroundWilbertz, T., Wagner, P., Petersen, K., Stiedl, A.-C., Scheble, V. J., Maier, S., Reischl, M., Mikut, R., Altorki, N. K., Moch, H., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.49 · Cited by 197 · cited 1×
“In contrast, SOX2 has been shown to correlate with improved survival and better patient outcome in lung cancer [48–53].”
BackgroundSOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell
Jia, X., Li, X., Xu, Y., Zhang, S., Mou, W., Liu, Y., Liu, Y., Lv, D., Liu, C.-H., Tan, X., et al. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr002 · Cited by 194 · cited 2×
“SOX2 has also been reported to promote cellular proliferation in breast, prostate, and cervical cancers, among others [30–32].”
BackgroundPolycomb recruitment to DNA in vivo by the YY1 REPO domain
Wilkinson, F. H., Park, K., & Atchison, M. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603564103 · Cited by 193
Transcriptional dynamics of endodermal organ formation
Sherwood, R. I., Chen, T. A., & Melton, D. A. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21810 · Cited by 191 · cited 1×
“b) SOX2 expression in various cancers SOX2 is expressed in neural stem cells [11], breast stem cells [12], and stem populations in the liver, pancreas, and stomach [13].”
BackgroundTsai, L.-L., Yu, C.-C., Chang, Y.-C., Yu, C.-H., & Chou, M.-Y. (2011) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2011.01015.x · Cited by 191 · cited 1×
“The elevated expressions of NANOG and OCT4 correlate with cisplatin resistance and recurrence in oral squamous cell carcinoma [115].”
BackgroundA nexus between Oct-4 and E1 A: Implications for gene regulation in embryonic stem cells
Schöler, H. R., Ciesiolka, T., & Gruss, P. (1991) · Cell · doi:10.1016/0092-8674(91)90619-a · Cited by 189
Oguro, H., Yuan, J., Ichikawa, H., Ikawa, T., Yamazaki, S., Kawamoto, H., Nakauchi, H., & Iwama, A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.01.005 · Cited by 185 · cited 2×
“c) BMI1 functions BMI1 is involved in the maintenance and/or selfrenewal of many stem cell types, including embryonic, neural, hematopoietic and prostate [92–95].”
BackgroundAmbrosetti, D.-C., Schöler, H. R., Dailey, L., & Basilico, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000932200 · Cited by 179 · cited 1×
“SOX2 and OCT4 interact directly to activate target gene transcription [61].”
BackgroundSatijn, D. P. E., Hamer, K. M., den Blaauwen, J., & Otte, A. P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1360-1369.2001 · Cited by 174 · cited 1×
“YY1 has been previously reported to directly interact with embryonic ectoderm development (EED), a protein of the same PcG family as BMI1 [137].”
BackgroundHan, X., Fang, X., Lou, X., Hua, D., Ding, W., Foltz, G., Hood, L., Yuan, Y., & Lin, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041335 · Cited by 171 · cited 1×
“SOX2 mediates invasive and migratory phenotypes, in part, through MMP3, MMP2, and PI3K/AKT/mTOR activations [35, 37, 39].”
BackgroundSiu, M. K. Y., Wong, E. S. Y., Kong, D. S. H., Chan, H. Y., Jiang, L., Wong, O. G. W., Lam, E. W.-F., Chan, K. K. L., Ngan, H. Y. S., Le, X.-F., et al. (2013) · Oncogene · doi:10.1038/onc.2012.363 · Cited by 165 · cited 1×
“e) Clinical implications Increased nuclear NANOG expression has been associated with high-grade subtypes of ovarian cancer and poor disease-free survival [84].”
BackgroundTargeted silencing of the oncogenic transcription factor SOX2 in breast cancer
Stolzenburg, S., Rots, M. G., Beltran, A. S., Rivenbark, A. G., Yuan, X., Qian, H., Strahl, B. D., & Blancafort, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks360 · Cited by 165
The basal‐like breast carcinoma phenotype is regulated by SLUG gene expression
Storci, G., Sansone, P., Trere, D., Tavolari, S., Taffurelli, M., Ceccarelli, C., Guarnieri, T., Paterini, P., Pariali, M., Montanaro, L., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2254 · Cited by 165 · cited 1×
“CD133+ breast CSCs with high SLUG expression have been shown to also have high BMI1 expression [102].”
BackgroundSOX2 expression and amplification in gliomas and glioma cell lines.
Annovazzi, L., Mellai, M., Caldera, V., Valente, G., & Schiffer, D. (2011) · PubMed · Cited by 162
Lee, S. H., Oh, S.-Y., Do, S. I., Lee, H. J., Kang, H. J., Rho, Y. S., Bae, W. J., & Lim, Y. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.528 · Cited by 161 · cited 2×
“e) Clinical implications SOX2 overexpression is correlated with tumor recurrence, poor prognosis and chemoresistance in head and neck squamous cell carcinoma [15].”
BackgroundOCT4: Dynamic DNA binding pioneers stem cell pluripotency
Jerabek, S., Merino, F., Schöler, H. R., & Cojocaru, V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.10.001 · Cited by 158 · cited 1×
“Among others, SALL4, ESRRB, and PAF1 have been implicated as positive regulators of OCT4 expression, while TCF3, GCNF, HIF and CDK2 have been identified as negative regulators [66].”
BackgroundExpression of transcription factor Yin Yang 1 in prostate cancer
Seligson, D. B., Horvath, S., Huerta‐Yépez, S., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.1.131 · Cited by 156 · cited 2×
“YY1 is overexpressed in many types of cancer, including metastatic breast cancer [129, 130], colon cancer [131], gastric cancer [132] and prostate cancer [133].”
BackgroundBMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas
Nowak, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl119 · Cited by 145 · cited 1×
“BMI1 levels are also elevated in various solid tumorforming cancers, among them neuroblastoma and bladder cancer [90, 91].”
BackgroundBooth, H., & Holland, P. (2004) · Genomics · doi:10.1016/j.ygeno.2004.02.014 · Cited by 139
Ibrahim, E. E., Babaei-Jadidi, R., Saadeddin, A., Spencer-Dene, B., Hossaini, S., Abuzinadah, M., Li, N., Fadhil, W., Ilyas, M., Bonnet, D., et al. (2012) · Stem Cells · doi:10.1002/stem.1182 · Cited by 135 · cited 1×
“While there are 11 NANOG pseudogenes [69], only pseudogene 8 has an open reading frame capable of producing the functional NANOG protein [69–72].”
BackgroundMohty, M., Yong, A. S. M., Szydlo, R. M., Apperley, J. F., & Melo, J. V. (2007) · Blood · doi:10.1182/blood-2006-12-065599 · Cited by 135 · cited 1×
“e) Clinical implications Elevated BMI1 RNA levels have been correlated with more advanced chronic myeloid leukemia status [96, 107].”
BackgroundWang, Q., He, W., Lu, C., Wang, Z., Wang, J., Giercksky, K. E., Nesland, J. M., & Suo, Z. (2009) · PubMed · Cited by 135
Prognostic significance of NANOG and KLF4 for breast cancer
Nagata, T., Shimada, Y., Sekine, S., et al. (2012) · Breast Cancer · doi:10.1007/s12282-012-0357-y · Cited by 130 · cited 1×
“Additionally, NANOG overexpression is correlated with poor prognoses for colorectal and breast cancer patients, as well as for ovarian cancer patients [85–87].”
BackgroundParanjape, A. N., Andugulapati, S. B., Mandal, T., Krushik, E. V., Nagaraj, P., Mukherjee, G., & Rangarajan, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-785 · Cited by 130 · cited 1×
“BMI1 overexpression correlates with NANOG overexpression, high-grade status and increased selfrenewal in breast adenocarcinomas [104].”
BackgroundSOX2 amplification is a common event in squamous cell carcinomas of different organ sites
Maier, S. H., Wilbertz, T., Braun, M., Scheble, V. J., Reischl, M., Mikut, R., Menon, R., Nikolov, P., Petersen, K., Beschorner, C., et al. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.11.010 · Cited by 121 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundNANOGP8 is a retrogene expressed in cancers
Zhang, J., Wang, X., Li, M., Han, J., Chen, B., Wang, B., & Dai, J. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05186.x · Cited by 119 · cited 1×
“While there are 11 NANOG pseudogenes [69], only pseudogene 8 has an open reading frame capable of producing the functional NANOG protein [69–72].”
BackgroundExpression of Sox2 in human cervical carcinogenesis
Ji, J., & Zheng, P. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.021 · Cited by 116 · cited 1×
“SOX2 has also been reported to promote cellular proliferation in breast, prostate, and cervical cancers, among others [30–32].”
BackgroundHan, J., Zhang, F., Yu, M., Zhao, P., Ji, W., Zhang, H., Wu, B., Wang, Y., & Niu, R. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.021 · Cited by 113 · cited 1×
“NANOG regulates the cell cycle and proliferation by directly binding the cyclin D1 promoter [75, 76].”
BackgroundSun, C., Sun, L., Li, Y., Kang, X., Zhang, S., & Liu, Y. (2013) · Medical Oncology · doi:10.1007/s12032-013-0503-1 · Cited by 111 · cited 1×
“SOX2 has been reported to promote invasion, migration, and metastasis in melanoma, colorectal cancer, glioma, gastric cancer, ovarian cancer and hepatocellular carcinoma [20, 35–38].”
BackgroundAssociation of OCT 4, SOX 2, and NANOG expression with oral squamous cell carcinoma progression
Fu, T., Hsieh, I., Cheng, J., Tsai, M., Hou, Y., Lee, J., Liou, H., Huang, S., Chen, H., Yen, L., et al. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12335 · Cited by 110 · cited 1×
“014) [74].”
SOX2 contributes to melanoma cell invasion
Girouard, S. D., Laga, A. C., Mihm, M. C., Scolyer, R. A., Thompson, J. F., Zhan, Q., Widlund, H. R., Lee, C., & Murphy, G. F. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.188 · Cited by 107 · cited 1×
“SOX2 mediates invasive and migratory phenotypes, in part, through MMP3, MMP2, and PI3K/AKT/mTOR activations [35, 37, 39].”
BackgroundXie, Z., Tan, G., Ding, M., Dong, D., Chen, T., Meng, X., Huang, X., & Tan, Y. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq715 · Cited by 105 · cited 1×
“In pluripotent stem cells, Foxm1 directly binds the POU5F1 promoter −3 kb upstream region [65].”
BackgroundThe cDNA sequence and chromosomal location of the human SOX2 gene
Stevanović, M. J., Zuffardi, O., Collignon, J., Lovell-Badge, R. H., & Goodfellow, P. N. (1994) · Mammalian Genome · doi:10.1007/bf00411460 · Cited by 105 · cited 1×
“Originally characterized in 1994, SOX2 is a member of the SOXB1 family of transcription factors, and its three primary domains are an N-terminal domain, a high-mobility group (HMG) domain, and a transactivation domain [9].”
BackgroundYin Yang 1 Plays an Essential Role in Breast Cancer and Negatively Regulates p27
Wan, M., Huang, W., Kute, T. E., Miller, L. D., Zhang, Q., Hatcher, H., Wang, J., Stovall, D. B., Russell, G. B., Cao, P. D., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.037 · Cited by 102 · cited 1×
“YY1 is overexpressed in many types of cancer, including metastatic breast cancer [129, 130], colon cancer [131], gastric cancer [132] and prostate cancer [133].”
BackgroundThe stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells
Hütz, K., Mejías‐Luque, R., Farsakova, K., Ogris, M., Krebs, S., Anton, M., Vieth, M. W., Schüller, U., Schneider, M. R., Blum, H., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt410 · Cited by 100 · cited 1×
“Furthermore, SOX2 has been implicated in the evasion of apoptotic signals in prostate cancer, gastric cancer and NSCLC [32–34].”
BackgroundSOX2 plays a critical role in EGFR-mediated self-renewal of human prostate cancer stem-like cells
Rybak, A. P., & Tang, D. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.041 · Cited by 98
SOX2 regulates apoptosis through MAP4K4-Survivin signaling pathway in human lung cancer cells
Chen, S., Li, X., Lü, D., Xu, Y., Mou, W., Wang, L., Chen, Y., Liu, Y., Li, X., Li, L., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt371 · Cited by 97 · cited 1×
“Furthermore, SOX2 has been implicated in the evasion of apoptotic signals in prostate cancer, gastric cancer and NSCLC [32–34].”
BackgroundFreier, K., Knoepfle, K., Flechtenmacher, C., Pungs, S., Devens, F., Toedt, G., Hofele, C., Joos, S., Lichter, P., & Radlwimmer, B. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20714 · Cited by 95 · cited 1×
“3 gene locus causes SOX2 amplification, which has been reported in glioblastoma, small-cell lung cancer and many squamous cell carcinomas [17–24].”
BackgroundRaaphorst, F. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi111 · Cited by 95 · cited 2×
“The polycomb repressive complex 2 (PRC2) is comprised of EED, EZH, Sux12 and YY1 [88].”
BackgroundLou, X., Xu, H., Jin, C., Tian, W., Yu, W., Ding, D., Cheng, L., Huang, B., Jiang, H., & Lin, B. (2013) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2013.0058 · Cited by 93 · cited 1×
“SOX2 has been reported to promote invasion, migration, and metastasis in melanoma, colorectal cancer, glioma, gastric cancer, ovarian cancer and hepatocellular carcinoma [20, 35–38].”
BackgroundSussman, R. T., Stanek, T. J., Esteso, P., Gearhart, J. D., Knudsen, K. E., & McMahon, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.469783 · Cited by 91
Transcription factor YY1 expression in human gastrointestinal cancer cells
Weber (2009) · International Journal of Oncology · doi:10.3892/ijo_00000270 · Cited by 90 · cited 1×
“YY1 is overexpressed in many types of cancer, including metastatic breast cancer [129, 130], colon cancer [131], gastric cancer [132] and prostate cancer [133].”
BackgroundYin, T., Wei, H., Gou, S., Shi, P., Yang, Z., Zhao, G., & Wang, C. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12031595 · Cited by 89 · cited 1×
“Furthermore, CD44+/CD24+ pancreatic cancer cells expressing high levels of BMI1 are largely resistant to gemcitabine [119].”
BackgroundThomassen, M., Tan, Q., & Kruse, T. A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-394 · Cited by 88 · cited 1×
“YY1 is overexpressed in many types of cancer, including metastatic breast cancer [129, 130], colon cancer [131], gastric cancer [132] and prostate cancer [133].”
BackgroundBMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
Crea, F., Serrat, M. A. D., Hurt, E. M., Thomas, S. B., Danesi, R., & Farrar, W. L. (2010) · International Journal of Cancer · doi:10.1002/ijc.25522 · Cited by 85 · cited 1×
“Docetaxel sensitivity is increased in prostate cancer cells by silencing BMI1 [116].”
BackgroundLi, J., Gong, L.-Y., Song, L.-B., Jiang, L.-L., Liu, L.-P., Wu, J., Yuan, J., Cai, J.-C., He, M., Wang, L., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090502 · Cited by 84 · cited 1×
“In glioma, BMI1 expression inversely correlates with survival and positively correlates with poor prognosis [110].”
BackgroundZinc finger proteins : from atomic contact to cellular function
井内, 史., & Kuldell, N. H. (2005) · Medical Entomology and Zoology · Cited by 83
Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
Wang, E., Bhattacharyya, S., Szabolcs, A., Rodriguez-Aguayo, C., Jennings, N. B., Lopez-Berestein, G., Mukherjee, P., Sood, A. K., & Bhattacharya, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017918 · Cited by 82 · cited 1×
“Ovarian CSCs are more resistant to cisplatin and paclitaxel when BMI1 is overexpressed [117], and targeting BMI1 sensitizes ovarian cancer cells to cisplatin [118].”
BackgroundExpression of NANOG in human gliomas and its relationship with undifferentiated glioma cells
Niu, C., Li, D.-X., Liu, Y., Fu, X.-M., Tang, S.-F., & Li, J. (2011) · Oncology Reports · doi:10.3892/or.2011.1308 · Cited by 79 · cited 1×
“The expressions of SOX2, OCT4 and NANOG correlate positively with the pathological grade of gliomas [54].”
BackgroundToschi, L., Finocchiaro, G., Nguyen, T. T., Skokan, M. C., Giordano, L., Gianoncelli, L., Perrino, M., Siracusano, L., Tommaso, L. D., Infante, M. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095303 · Cited by 78
Kang, W., TONG, J. H. M., Chan, A. W. H., Zhao, J., Dong, Y., Wang, S., Yang, W., Sin, F. M., Ng, S. S., Yu, J. Q., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-80 · Cited by 77 · cited 1×
“YY1 is overexpressed in many types of cancer, including metastatic breast cancer [129, 130], colon cancer [131], gastric cancer [132] and prostate cancer [133].”
BackgroundPrognostic Impact of the Cancer Stem Cell-Related Marker NANOG in Ovarian Serous Carcinoma
Kim, J., Kim, Y. T., Lee, M., Nam, E. J., Kim, S. W., & Kim, S. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igj.0b013e3182738307 · Cited by 76 · cited 1×
“Additionally, NANOG overexpression is correlated with poor prognoses for colorectal and breast cancer patients, as well as for ovarian cancer patients [85–87].”
BackgroundYin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis
Wang, A.-M., Huang, T.-T., Hsu, K.-W., Huang, K.-H., Fang, W.-L., Yang, M.-H., Lo, S., Chi, C., Lin, J.-J., & Yeh, T.-S. (2014) · OncoTarget · doi:10.18632/oncotarget.2073 · Cited by 76 · cited 1×
“Additionally, YY1 upregulates NANOG in gastric cancer [136].”
BackgroundYadırgı, G., Leinster, V. H. L., Acquati, S., Bhagat, H., Shakhova, O., & Marino, S. (2011) · Stem Cells · doi:10.1002/stem.614 · Cited by 75 · cited 2×
“c) BMI1 functions BMI1 is involved in the maintenance and/or selfrenewal of many stem cell types, including embryonic, neural, hematopoietic and prostate [92–95].”
BackgroundNanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells
Moon, J.-H., Kwon, S., Jun, E. K., Kim, A., Whang, K. Y., Kim, H., Oh, S., Yoon, B. S., & You, S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.070 · Cited by 72 · cited 1×
“Furthermore, NANOG is capable of inducing CSClike properties in primary p53-deficient mature mouse astrocytes; however, astrocytes with intact p53 could not be induced [78].”
BackgroundHuber, G. F., Albinger‐Hegyi, A., Soltermann, A., Roessle, M., Graf, N., Haerle, S. K., Holzmann, D., Moch, H., & Hegyi, I. (2011) · Cancer · doi:10.1002/cncr.26100 · Cited by 71 · cited 1×
“b) BMI1 expression in various cancers BMI1 expression levels have been reported to be high in many tissues, including the brain, esophagus, kidney, lungs, and blood, among others [89].”
BackgroundVormittag, L., Thurnher, D., Geleff, S., Pammer, J., Heiduschka, G., Brunner, M., Grasl, M. C., & Erović, B. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.040 · Cited by 69 · cited 1×
“considered to be a predictive factor for overall survival [109].”
BackgroundBonavida, B., & Kaufhold, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.011 · Cited by 69 · cited 1×
“Patterns of YY1 protein expression levels in human cancers have been reviewed previously [134].”
BackgroundSelf-citationSOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
Dhodapkar, K. M., Gettinger, S. N., Das, R., Zebroski, H. A., & Dhodapkar, M. V. (2013) · OncoImmunology · doi:10.4161/onci.25205 · Cited by 63
How Sox2 maintains neural stem cell identity
Thiel, G. (2013) · Biochemical Journal · doi:10.1042/bj20130176 · Cited by 61 · cited 1×
“b) SOX2 expression in various cancers SOX2 is expressed in neural stem cells [11], breast stem cells [12], and stem populations in the liver, pancreas, and stomach [13].”
BackgroundTargeting self-renewal, an Achilles' heel of cancer stem cells
Wicha, M. S. (2014) · Nature Medicine · doi:10.1038/nm.3434 · Cited by 56 · cited 1×
“d) Regulation of BMI1 Multiple major regulatory pathways, including Akt, Wnt and Notch, contribute to the regulation of BMI1 [105].”
BackgroundLi, D., Zhao, L., Zheng, X., Lin, P., LIN, F., Li, Y., ZOU, H.-F., Cui, R., Chen, H., & Yu, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2630 · Cited by 56 · cited 2×
“The PI3K/Akt signaling pathway has been shown to be activated in prostate cancer cells overexpressing SOX2 [44].”
BackgroundDifferential expression of stem cell markers and ABCG2 in recurrent prostate cancer
Güzel, E., Karataş, Ö. F., Düz, M. B., Solak, M., Ittmann, M., & Özen, M. (2014) · The Prostate · doi:10.1002/pros.22867 · Cited by 56 · cited 10×
“SOX2 and OCT4 interact directly to activate target gene transcription [61].”
BackgroundInfluentialChoi, S., Choi, J.-H., Park, C., Ahn, C., Hong, S. J., & Lim, D. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24076 · Cited by 52 · cited 1×
“NANOG regulates the cell cycle and proliferation by directly binding the cyclin D1 promoter [75, 76].”
BackgroundLi, Y., Chen, K., Li, L., Li, R., Zhang, J., & Ren, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-3561-5 · Cited by 48 · cited 1×
“By contrast, ovarian adenocarcinoma cells overexpressing SOX2 have been reported to possess an inhibited PI3K/Akt signaling pathway [45].”
BackgroundHigh SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
Velcheti, V., Schalper, K. A., Yao, X., Cheng, H., Kocoglu, M. H., Dhodapkar, K. M., Deng, Y., Gettinger, S. N., & Rimm, D. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061427 · Cited by 46
Fang, W., Fan, C., Li, S., Jang, T., Lin, H.-P. P., Shih, N., Chen, C., Wang, T., Huang, S.-F. K., Lee, A. Y., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28734 · Cited by 42 · cited 2×
“The upregulation of BMP4, which acts as a tumor suppressor, is responsible for this inhibition of proliferation [28].”
BackgroundThe interactomes of POU5F1 and SOX2 enhancers in human embryonic stem cells
Gao, F., Wei, Z., An, W., Wang, K., & Lu, W. (2013) · Scientific Reports · doi:10.1038/srep01588 · Cited by 35 · cited 8×
“a) General properties of OCT4 The POU5F1 gene is located on chromosome 6p21.”
BackgroundInfluentialFAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Golubovskaya, V. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313040006 · Cited by 31 · cited 1×
“P53 directly binds the NANOG promoter through two consensus binding motifs [82].”
BackgroundDoğan, İ., Kawabata, S., Bergbower, E. A. S., Gills, J. J., Ekmekçi, A., Wilson, W., Rudin, C. M., & Dennis, P. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.021 · Cited by 31 · cited 1×
“Lung adenocarcinoma cell lines are sensitized to erlotinib by shRNA-knockdown of SOX2 [50].”
BackgroundNANOGP8: Evolution of a Human-Specific Retro-Oncogene
Fairbanks, D. J., Fairbanks, A. D., Ogden, T. H., Parker, G. J., & Maughan, P. J. (2012) · G3 Genes Genomes Genetics · doi:10.1534/g3.112.004366 · Cited by 26
Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer
Du, Y., Shi, L.-Z., Wang, T., Liu, Z., & Wang, Z. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1253-8 · Cited by 26 · cited 1×
“The overexpression of NANOG promotes cisplatin resistance in esophageal cancer [113], and siRNAknockdown of NANOG increases sensitivity to cisplatin [114].”
BackgroundOverexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report.
Shafaroudi, A. M., Mowla, S. J., Ziaee, S. A. M., Bahrami, A. R., Atlasi, Y., & Malakootian, M. (2008) · Urology journal./Urology jornal. · Cited by 24
Do, H., Lee, W., Lim, H., Oh, J., Kim, D., Kim, J., Kim, T., & Kim, J. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22089 · Cited by 22 · cited 1×
“OCT4/SOX2 heterodimers bind the NANOG proximal promoter region to induce transcription [62, 63].”
BackgroundLiu, H., & Shi, Y. (2007) · Springer eBooks · doi:10.1007/0-387-27421-9_25 · Cited by 10
Cited by
The Why of YY1: Mechanisms of Transcriptional Regulation by Yin Yang 1
Verheul, T. C. J., van Hijfte, L., Perenthaler, E., & Barakat, T. S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.592164 · Cited by 196
Puhr, M., Hoefer, J., Eigentler, A., Ploner, C., Handle, F., Schaefer, G., Kroon, J., Leo, A., Heidegger, I., Eder, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0989 · Cited by 171
“Yin Yang 1 supports proliferation, EMT, and metastases (42) and has been frequently found upregulated in prostate cancer (43).”
BackgroundTargeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6
Metadata
- Authors
- Kaufhold, S., Garbán, H., & Bonavida, B.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2016-05-25
- Volume
- 35
- Issue
- 1
- Pages
- 84-84
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2395905799
- Cited by
- 166
- References
- 130
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.